Partnership has successfully completed analytical validation of a cheek swab collection solution for testing and identifying patients with the genotypes important for AD04 developmentGLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the successful completion of the analytical val ...

Upgrades Summary - Morgan Stanley upgraded Celsius Holdings (CELH) to Overweight from Equal Weight with a price target of $70, up from $61, citing a return to growth and expected reacceleration in topline growth due to easier comparisons from December through early June [2] - UBS upgraded FIS (FIS) to Buy from Neutral with an unchanged price target of $82, believing the risk/reward profile has improved as shares are down 20% year-to-date [2] - Oppenheimer upgraded Semtech (SMTC) to Outperform from Perform with a price target of $81, following positive management meetings and a bullish outlook on growth opportunities in data center artificial intelligence [2] - BofA upgraded Freeport-McMoRan (FCX) to Buy from Neutral with an unchanged price target of $42, expressing increased confidence in the current valuation despite risks associated with the halted Grasberg copper/gold mine in Indonesia [2] - Maxim upgraded Adial Pharmaceuticals (ADIL) to Buy from Hold with a price target of $1.50, reflecting a more bullish stance on the company [2]

GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced receipt of the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held on July 29, 2025. The minutes provide the FDA’s formal input into the AD04 Phase 3 adaptive clinica ...

Core Points - Adial Pharmaceuticals has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share, now having until March 2, 2026 to meet this requirement [1][2] - The company must maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during the extension period [2] - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 showing promising results in a Phase 3 clinical trial for Alcohol Use Disorder [3] Company Overview - Adial Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing treatments for addictions and related disorders [3] - The lead investigational drug, AD04, is a genetically targeted serotonin-3 receptor antagonist aimed at treating Alcohol Use Disorder and potentially other addictive disorders [3]

Core Viewpoint - Adial Pharmaceuticals, Inc. (ADIL) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on an upward trend in earnings estimates, which significantly influences stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements. Institutional investors often adjust their valuations based on these estimates, leading to buying or selling actions that affect stock prices [4][6]. - For the fiscal year ending December 2025, Adial Pharmaceuticals is expected to earn -$0.54 per share, unchanged from the previous year. However, the Zacks Consensus Estimate for the company has increased by 49.5% over the past three months, reflecting a positive trend in earnings outlook [8]. Zacks Rank System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell). Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, showcasing the effectiveness of this system [7]. - The upgrade of Adial Pharmaceuticals to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks regarding estimate revisions, suggesting potential for market-beating returns in the near term [10].

About Adial Pharmaceuticals, Inc. Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, being developed for the treatment of Alcohol Use Disorder (AUD). AD04 was recently investigated in a Phase 3 clinical trial ONWARD™ and showed promising results with reduced drinking in patients with AUD, and was ...

[FORM 8-K Filing Information](index=1&type=section&id=FORM%208-K%20Filing%20Information) This section provides an overview of the Form 8-K filing, including registrant details and report specifics [Registrant Information](index=1&type=section&id=Registrant%20Information) This section provides essential identification details for Adial Pharmaceuticals, Inc., including its legal and operational information, and its status as an emerging growth company - Adial Pharmaceuticals, Inc. is a Delaware corporation[2](index=2&type=chunk)[3](index=3&type=chunk) Registrant Details | Detail | Value | | :--- | :--- | | Exact Name of Registrant | Adial Pharmaceuticals, Inc. | | State of Incorporation | Delaware | | Trading Symbol | ADIL | | Exchange Registered | The Nasdaq Stock Market LLC (Nasdaq Capital Market) | | Emerging Growth Company | Yes | [Filing Details](index=1&type=section&id=Filing%20Details) This section specifies the date of the report and confirms the filing is a Current Report on Form 8-K, indicating it is not intended to satisfy other specific filing obligations - The report date is August 14, 2025, for the earliest event reported on the same date[2](index=2&type=chunk) - The filing is a Current Report on Form 8-K, not simultaneously satisfying other specified filing obligations under Rule 425, Rule 14a-12(b), Rule 14d-2(b), or Rule 13e-4(c)[2](index=2&type=chunk)[3](index=3&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section reports the company's financial performance for the quarter, including the announcement and legal disclaimers [Announcement of Financial Results](index=2&type=section&id=Announcement%20of%20Financial%20Results) Adial Pharmaceuticals, Inc. announced its financial results for the fiscal quarter ended June 30, 2025, through a press release furnished as an exhibit to this 8-K report - On August 14, 2025, Adial Pharmaceuticals, Inc. issued a press release containing financial information for the fiscal quarter ended June 30, 2025[5](index=5&type=chunk) - A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K[5](index=5&type=chunk) [Legal Disclaimer](index=2&type=section&id=Legal%20Disclaimer) The company clarifies that the financial information provided in this Item 2.02 and the accompanying press release is furnished, not filed, and is therefore not subject to certain liabilities or incorporated by reference into other SEC filings - The information in Item 2.02 and Exhibit 99.1 is not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934[6](index=6&type=chunk) - The information is not subject to the liabilities of Section 18 or Sections 11 and 12(a)(2) of the Securities Act of 1933[6](index=6&type=chunk) - The information shall not be incorporated by reference into any other SEC filing made by the Company[6](index=6&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section details the financial statements and other documents included as exhibits to the Form 8-K filing [List of Exhibits](index=2&type=section&id=List%20of%20Exhibits) This section lists the documents furnished as exhibits to the Form 8-K, primarily the press release detailing the financial results and the interactive data file Exhibit List | Exhibit Number | Exhibit Description | | :--- | :--- | | 99.1 | Press Release, issued by Adial Pharmaceuticals, Inc. on August 14, 2025 | | 104 | Cover Page Interactive Data File (XBRL) | [SIGNATURES](index=3&type=section&id=SIGNATURES) This section provides the formal authorization and signatory details for the filed report [Authorization and Signatory](index=3&type=section&id=Authorization%20and%20Signatory) This section formally concludes the report with the required signatures, confirming the registrant's authorization and the identity of the signing officer - The report was duly signed on behalf of ADIAL PHARMACEUTICALS, INC. pursuant to the requirements of the Securities Exchange Act of 1934[10](index=10&type=chunk) Signatory Details | Detail | Value | | :--- | :--- | | Date | August 14, 2025 | | Signatory Name | Cary J. Claiborne | | Signatory Title | President and Chief Executive Officer |

GLEN ALLEN, Va., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the second quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, "We believe we are at an inflection point in Adial's journey. With the successful complet ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-38323 ADIAL PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 82-3074668 | ...

Meeting Completion Marks Major Step Toward Phase 3 AD04 Trial Launch Strategic Partnership Discussions Expected Following the Positive FDA Meeting GLEN ALLEN, Va., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the completion of a successful End of Phase 2 meeting (EOP2M) with the Food and Dru ...